Diamyd Medical News and Activities

Diamyd Medical is a company listed under the stock ticker DMYD (SE).

View the org chart displaying its 20 main executives

Most searched biographies at Diamyd Medical

• Anders Essen-Möller, Chief Executive Officer
• Karin Rosen, Director
• Karin Hehenberger, Director

Popular executive movements at Diamyd Medical

• Niklas Axelsson, Chief Financial Officer, has left the company  (posted on May 25 2026).
• Erik Nerpin, who was Vice Chairman of the Board, is promoted to Chairman of the Board  (posted on April 27 2026).
• Anders Essen-Möller, who was Executive Chairman of the Board, is promoted to Chief Executive Officer  (posted on April 27 2026).

Click here to view some more movements at Diamyd Medical

Create your alert
to follow the executive moves at Diamyd Medical.

Diamyd Medical has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by Diamyd Medical

• Diamyd Medical announces that Niklas Axelsson has decided to leave his position as CFO to take on a new role in another company
• Diamyd Medical receives GMP certification and manufacturing authorization for biological investigational medicinal products for human use
• Diamyd Medical provides an update on strategic review and financial position
• Diamyd Medical strengthens its position in the manufacturing of biological medicines – positive feedback from the Swedish Medical Products Agency
• Diamyd Medical updates U.S. market potential for Diamyd®
• Renowned immunology investigator, Alice Long, joins Diamyd Medical’s Scientific Advisory Board
• Diamyd Medical confirms key advances toward Accelerated Approval for Diamyd® following FDA Type C Meeting
• South Korea to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in autoimmune diabetes
• New publication highlights safety and potential benefits of redosing Diamyd® precision medicine for Type 1 Diabetes
• Renowned Diabetes Investigator, Emily Sims, Joins Diamyd Medical’s Scientific Advisory Board
• View more press releases Close

Social media about Diamyd Medical

• Diamyd Medical on Wikipedia, Google News & Yahoo Finance
• Diamyd Medical on LinkedIn, X (Twitter) & YouTube